Vol 8, Supp. C (2017)
Case report
Published online: 2017-12-31

open access

Page views 879
Article views/downloads 2077
Get Citation

Connect on Social Media

Connect on Social Media

Ostra białaczka szpikowa w przebiegu pierwotnego włóknienia szpiku leczona azacytydyną

Małgorzata Raźny1, Paweł Szwedyk

Abstract

Pierwotne włóknienie szpiku (PMF), schorzenie należące do klonalnych przewlekłych nowotworów mieloproliferacyjnych, w 10–20% przypadków ulega transformacji do ostrej białaczki szpikowej (AML). W niniejszym artykule przedstawiono przypadek pacjenta, u którego nastąpiła transformacja PMF do AML, poddanego leczeniu azacytydyną.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Góra-Tybor J. Pierwotna mielofibroza. In: Warzocha K. ed. Nowotwory mieloproliferacyjne, zespoły mielodysplastyczne i mastocytoza. Biblioteka czasopisma Hematologia. Tom 2. Via Medica, Gdańsk 2017: 52–65.
  2. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014; 28(9): 1804–1810.
  3. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014; 124(24): 3529–3537.
  4. Bose P, Verstovsek S. Myelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother. 2016; 17(18): 2375–2389.
  5. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005; 105(3): 973–977.
  6. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008; 112(5): 1628–1637.
  7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3): 223–232.
  8. Seymour JF, Bennett JM, List AF, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Br J Haematol. 2014; 165(1): 49–56.
  9. Sanna A, Gozzini A, Donnini I, et al. 317 Influence of mild bone marrow fibrosis on response of int-2/high risk MDS patients to 5-azacitidine. Leuk Res. 2011; 35: S126–S127.
  10. Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015; 39(9): 950–956.
  11. Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010; 34(9): 1246–1249.
  12. Thepot S, Itzykson R, Seegers V, et al. Groupe Francophone des Myelodysplasies (GFM). Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010; 116(19): 3735–3742.
  13. Mwirigi A, Galli S, Keohane C, et al. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2014; 167(5): 714–716.
  14. Ye X, Chen D, Zheng Y, et al. Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms. Onco Targets Ther. 2017; 10: 5425–5428.



Hematology in Clinical Practice